Read Summary

Nivolumab (Opdivo) with chemotherapy or in combination with ipilimumab (Yervoy) has been approved by the FDA for first-line use in the treatment of unresectable advanced or metastatic esophageal cancer.
FDA Approvals

Print Friendly, PDF & Email